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Fluorescence in situ hybridization (FISH) provides an
important adjunct to conventional cytogenetics and
molecular studies in the evaluation of chromosome
abnormalities associated with hematologic malignan-
cies. FISH employs DNA probes and methods that are
generally not Food and Drug Administration-ap-
proved, and therefore, their use as analyte-specific
reagents involves unique pre- and postanalytical re-
quirements. We provide an overview of the technical
parameters influencing a reliable FISH result and en-
courage laboratories to adopt specific procedures and
policies in implementing metaphase and interphase
FISH testing. A rigorous technologist training pro-
gram relative to specific types of probes is detailed, as
well as guidance for consistent interpretation of find-
ings, including typical and atypical abnormal results.
Details are provided on commonly used dual-fusion,
extra signal, and break-apart probes, correct FISH
nomenclature in the reporting of results, and the use
of FISH in relation to other laboratory testing in the
ongoing monitoring of disease. This article provides
laboratory directors detailed guidance to be used in
conjunction with existing regulations to successfully
implement a FISH testing program or to assess cur-
rent practices, allowing for optimal clinical testing
for patient care. (J Mol Diagn 2007, 9:134–143; DOI:
10.2353/jmoldx.2007.060128)
The World Health Organization recent classification of tu-
mors of hematopoietic and lymphoid tissues emphasizes
the importance of chromosome abnormalities for accurate
diagnosis, appropriate treatment, and monitoring response
to therapy.1 In certain scenarios, fluorescence in situ hybrid-
ization (FISH) analysis offers one of the most sensitive,
specific, and reliable strategies for identifying acquired
chromosomal changes associated with hematologic disor-
ders. With the growth in the understanding of the impor-
tance of cytogenetic abnormalities associated with these
diseases and the availability of commercial FISH probes,
this area of clinical laboratory testing is rapidly expanding.
Here, we offer guidance for initiating, validating, routinely
performing, and reporting FISH studies for hematologic dis-
orders. The recommendations in this article provide de-
tailed assistance for implementing FISH testing and are
meant to assist laboratories with complying with existing
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regulations and guidelines from the Clinical Laboratory Im-
provement Amendments (CLIA), the American College of
Medical Genetics (ACMG), and the College of American
Pathologists.
FISH Procedures and Probes
The FISH methods widely used in clinical laboratory stud-
ies involve hybridization of a fluorochrome-labeled DNA
probe to an in situ chromosomal target. FISH can be
applied to a variety of specimen types. Metaphase prep-
arations from cultured cells that are routinely used for
cytogenetic analysis are considered the “gold standard”
because chromosome morphology and position of the
signals can be visualized directly. However, a major ad-
vantage of FISH is that it can also be performed on
nondividing interphase cells. Interphase nucleus assess-
ment from uncultured preparations allows for a rapid
screening for specific chromosome rearrangements or
numerical abnormalities associated with hematologic
malignancies. Interphase analysis may also be per-
formed on bone marrow cell suspensions routinely used
for conventional cytogenetics, paraffin-embedded tissue
sections, or disaggregated cells from paraffin blocks,
bone marrow, or blood smears, and touch-preparations
of cells from lymph nodes or solid tumors.
Pre-Analytical Issues
Clinical Indications for FISH Analysis
The initial assessment of many hematologic malignancies
typically includes morphological, histological, immuno-
phenotypic (flow cytometric and/or immunohistochemi-
cal), and conventional cytogenetic analyses. Data
gleaned from cytogenetic analysis can be pathogno-
monic for specific leukemias in the World Health Organi-
zation classification (for example, acute myeloid leuke-
mias with recurrent cytogenetic abnormalities and
chronic myelogenous leukemia) and are likely to assume
an even greater role in defining specific entities in future
classifications.1 Despite conventional karyotyping’s cur-
rent role as the standard for such definitions, it has be-
come clear that FISH studies may also be an integral
component of the diagnostic evaluation, particularly
where the abnormality is “cryptic” (ie, not evident by
conventional karyotyping).
Although somewhat overlapping, FISH can be consid-
ered to be of special utility in the following diagnostic
scenarios (Table 1): 1) abnormalities with a low fre-
quency, but well-documented percentage, of false-neg-
ative cytogenetic results, particularly in scenarios where
the clinical, hematologic, and pathological parameters
suggest a specific abnormality; 2) abnormalities with a
high frequency of “false-negative” cytogenetics; 3) inter-
phase analysis, when conventional cytogenetics fails or
is not possible, for example, on fixed tissue; 4) to clarify
abnormal or complex conventional karyotypic findings;
and 5) as a surrogate marker for a primary genetic event.
For example, when FISH is the preferred laboratory
method, it is recommended that cases of chronic myelog-
enous leukemia (CML) be studied at diagnosis by cyto-
genetic analysis and molecular cytogenetic methods to
determine the initial clonal abnormalities and the FISH
signal pattern both for prognostic information and for
follow-up studies, respectively.2 In acute lymphoblastic
leukemia (ALL), where the genetics of the leukemic cells
are frequently used for risk stratification and therapeutic
decisions, FISH can be used to detect BCR/ABL1,
ETV6(TEL)/RUNX1(AML1), and MLL gene rearrange-
ments and hyperdiploidy with extra copies of chromo-
somes 4, 10, and 17. In acute myeloid leukemia (AML),
FISH to detect CBFA2T1(ETO)/RUNX1, PML/RARA,
CBFB/MYH11, and MLL gene rearrangements may be
performed, as indicated based on the morphological and
immunophenotypic findings in the bone marrow.3 When
acute promyelocytic leukemia is the suspected diagno-
sis, FISH, or another method with rapid turnaround time,
should be performed as quickly as possible with same-
day or next-day turnaround to allow for timely treatment
with all-trans-retinoic acid.4
In some of these diagnostic situations, polymerase
chain reaction (PCR)-based assays can be performed
Table 1. Major Indications for Performing FISH at Diagnosis
1) To detect abnormalities usually* detected by CC
AML t(8;21)/CBFA2-ETO, t(15;17)/PML-RARA, inv(16)/CBFB-MYH11
CML t(9;22)/BCR-ABL1
B-ALL t(1;19)/E2A- PBX1, t(?;11)/MLL, t(9;22)/BCR-ABL1, hyperdiploidy
2) To detect abnormalities not usually† detected by CC
CLL/SLL del(13q14)/?miRNA15–16, del(11q22)/?ATM, del(17p13)/TP53, 12
PCM del(13q14), hyperdiploidy, t(4;14)/FGFR3-IGH
B-ALL t(12;21)/ETV6-RUNX1, t(?;11)/MLL
T-ALL t(5;14)/HOX11L2-, del(1p)/SIL-SCL, episomal amplification 9q34/NUP214-ABL1
CEL del(4q12)/FIP1L1-PDGFRB
3) No metaphases
4) Clarification of complex CC
5) Surrogate marker
CEL CHIC2 deletion as a marker of del(4q12)/FIP1L1-PDGFRB
CC, conventional cytogenetics; B-ALL, precursor B-cell acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic
lymphoma; PCM, plasma cell myeloma; T-ALL, precursor T-cell acute lymphoblastic leukemia; CEL, chronic eosinophilic leukemia.
*Usually indicates false-negative CC in 5 to 10% of cases.
†Not usually indicates that 50 to 100% of these abnormalities might be missed by CC.
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instead of FISH analysis, with the decision of which assay
to perform often dictated by factors such as local exper-
tise/availability of the appropriate technology. However,
one exception to this generalization is for the detection of
numeric abnormalities (gains and losses of whole chro-
mosomes or deletions/duplications), where FISH is
clearly superior to PCR-based assays. Furthermore, there
are also well-documented scenarios in which FISH is
preferred to PCR-based assays, in particular, DNA-
based assays, where breakpoint heterogeneity compro-
mises the diagnostic utility of the PCR assay. Examples of
such false-negative PCR assays include detection of the
t(11;14)/CCND1-IGH translocation in mantle cell lym-
phoma and t(14;18)/IGH-BCL2 translocation in follicular
lymphoma. In addition to these false negatives, there is
the potential concern of false-positive PCR results as a
result of contamination or the detection of disease-asso-
ciated gene fusions in normal individuals. Whereas some
studies have proposed a role for FISH in minimal residual
disease analysis, in situations where PCR-based assays
are available, the latter are clearly preferred given their
greater analytic sensitivity.
For mature B-cell disorders, genetic studies provide
important independent prognostic information. Routine
cytogenetic analyses often yield normal results be-
cause of the poor in vitro growth of mature B-cell pop-
ulations; therefore, FISH is a useful tool for detecting
chromosomal aberrations. For chronic lymphocytic leu-
kemia/small lymphocytic lymphoma, FISH allows for
patient stratification into good (deletion 13q14), inter-
mediate (trisomy 12), and poor (deletion of ATM and
deletion of TP53) prognosis categories, in addition to
providing a means to monitor disease progression.5,6
For plasma cell myeloma, FISH for deletion 13q14 or
monosomy 13, translocations involving chromosome
14, especially t(4;14), trisomy of chromosomes 7, 9,
and 15, and deletion of the TP53 gene provide prog-
nostic information.7
FISH can be a useful tool to monitor remission status
when clonal chromosome abnormalities have been iden-
tified at diagnosis and appropriate probes are available.
For CML, sequential FISH studies can be useful to deter-
mine changes in clinical status in response to therapy
and to assess for residual disease in concert with reverse
transcription-PCR analysis for BCR/ABL1. In situations
where PCR-based assays are available, these are the
preferred methodology for minimal residual disease as-
sessment given their greater analytic sensitivity. In pa-
tients with sex-mismatched bone marrow transplants for
whom graft rejection, marrow suppression, or disease
relapse is a clinical consideration, monitoring with a FISH
assay that combines sex chromosome probes with or
without probes to detect the patient’s clonal abnormality
can be valuable for graft assessment and to detect
residual or recurrent disease.
FISH Test Validation
There are only a few commercially manufactured probe
kits that have been approved by the Food and Drug
Administration for in vitro diagnostic testing. These FISH
kits must meet the sensitivity and specificity parameters
stated in package inserts provided by the manufacturer.
The majority of probes used for clinical FISH testing
are considered analyte-specific reagents, ie, reagents
that are produced under good manufacturing practice
guidelines set forth by the Food and Drug Administration,
but their safety and efficacy must be established by the
user. When a new analyte-specific reagent probe is in-
troduced in the laboratory, extensive validation is
needed, including specific validation of the probe itself
(probe validation) and validation of the procedures using
the probe (analytical validation) (ACMG. Standards and
Guidelines for Clinical Genetic Laboratories, Section E:
Clinical Cytogenetics. http://www.acmg.net, accessed De-
cember 12, 2005).8 Initially, it is important to become
familiar with a probe’s parameters, including signal inten-
sity and pattern and any cross-hybridization that is likely
to confound test results. This can be accomplished by
assessing probe characteristics on several known posi-
tive and/or negative specimens. Probe validation con-
sists of localizing the probe to the correct chromosomal
band on normal metaphase cells and determining its
sensitivity and specificity (ACMG Standards and Guide-
lines for Clinical Genetic Laboratories, Section E: Clinical
Cytogenetics). Probes may be localized by hybridization
to metaphase cells with identification of the appropriate
target chromosome region using reverse 4,6-diamino-2-
phenol-indole chromosomal staining, sequential G-, R-,
or Q-chromosome banding to FISH, or other methods that
allow for specific chromosome identification. Localization
should ensure that the tested probe is the intended probe
and that there is no probe contamination or significant
cross-hybridization. Probe sensitivity, defined as the per-
centage of metaphases with the expected signal pattern
at the correct chromosomal location, should be estab-
lished by analysis of the hybridization of the probe to
chromosomes representing at least 200 distinct genomic
targets derived from each of at least five control male
individuals (includes all 24 haploid chromosomes). The
genomic targets may represent distinct chromosomes or
distinct chromatids depending on the location of the
probe. Likewise, probe specificity, or the percentage of
signals that hybridize to the correct locus and no other
location, may be assessed by studying at least 200 cells
from a minimum of five male individuals. An adequate
number of cells and loci should be scored to ensure that
the probe has the sensitivity and specificity required for
the clinical testing being performed.9 Probes used for
hematologic malignancy studies should have a high an-
alytic sensitivity and specificity (95%), particularly if
they are to be used for minimal residual disease
assessment.
Analytical validation requires an appreciation of probe
and test parameters that allows for interpretation of the
FISH result. Analytical validation for metaphase cell anal-
ysis is inherent in the probe validation process. For
probes that will be used for interphase cell analysis,
analytical validation requires normal reference ranges be
calculated from the evaluation of cytogenetically charac-
terized cases. The data are used to establish cutoffs for
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designating a result as normal or abnormal (ie, distin-
guishing true positives from false positives). One way to
establish a normative database for a dual-color, dual-
fusion BCR/ABL1 probe for bone marrow samples would
be to gather data from at least 500 interphase cells from
bone marrow samples from each of 20 BCR/ABL1 fusion-
negative individuals. For paraffin-embedded tissues, a
normative database for a dual-color, dual-fusion probe
could be generated by assessing the signal patterns for
all of the available disease tissue (if there are less than
500 cells available) from 20 individuals without the rear-
rangement being validated. The normal cutoff point
would be determined by statistical analysis using a bi-
nominal distribution assessment.10 Because the normative
data are not distributed in a typical bell-shaped curve, cutoff
points cannot be based on SD calculations.10
The normal cutoff for an analysis of 200 cells can be
calculated for FISH results using the Microsoft Excel  in-
verse function,  BETAINV(Confidence level, false-positive
cells plus 1, number of cells analyzed).10 This formula cal-
culates a one-sided upper confidence limit for a specified
percentage proportion based on an exact computation for
the binomial distribution. This can be done by examining
results for 20 normal specimens for the particular sample
type being validated and identifying the specimen with the
greatest number of false-positive nuclei for any given signal
pattern. This number of false-positive cells is inserted into
the  inverse function to determine the normal cutoff for
detection of a true abnormal clone. To illustrate how to
calculate the normal cutoff, consider the following example
for a 95% confidence level in which four false-positive cells
for any given signal pattern were identified among 200
nuclei. In the formula bar in Microsoft Excel, enter: 
BETAINV(0.95,5200); the result is 4.43% cutoff or 8.86 cells.
In other words, the formula would read  BETAINV(0.95
upper bound percentile, four false-positive cells plus 1,
analysis of 200 cells). Based on this calculation, 9.0 cells is
the abnormal cutoff because fractions of cells cannot be
analyzed. The observation of 9.0 or more cells with the
aberrant pattern in a study of a total of 200 cells analyzed
would be an abnormal result. Note that a normal cutoff
needs to be established for different levels of cells counted.
Hence, the initial assessment for the database generation of
500 nuclei for 20 control individuals can be used to estab-
lish cutoffs for 200, 250, or 300 cells, or whatever the labo-
ratory determines to be a clinically relevant number of cells
to score.
To validate a FISH test, known normal and abnormal
cases should be assessed to establish clearly defined
scoring criteria for determining that the assay is accept-
able. Laboratories may choose to have a series of cases
split between the home institution and a reference labora-
tory. Results should be compared, including images of the
hybridization patterns. The clinical test should not be of-
fered until the Laboratory Director is confident of the labo-
ratory’s ability to produce accurate results following a re-
view of the data from the parallel series and investigation of
the reason for any discrepant results. CLIA regulations re-
quire that there also be biannual or continuous review of the
performance characteristics of each FISH test to assess for
trends that might suggest problems with the assay (ACMG
Standards and Guidelines for Clinical Genetic Laboratories,
Section E: Clinical Cytogenetics). In addition to continuous
quality monitoring of individual probes, biannual proficiency
testing must be performed on each FISH category.
Analytical Issues
Staff Training
Ideally, at least one individual in the laboratory should
have considerable experience and expertise in FISH.
Experience may be obtained from attending course of-
ferings or sponsored workshops or from visiting another
laboratory with the expertise.
Laboratories should maintain a FISH training manual in
which each probe or probe set used is described. Pho-
tographic images or drawings of abnormal patterns (both
simple abnormal patterns and more complex variant pat-
terns) and normal patterns should be included, along
with helpful comments regarding the use of particular
probes. Probe manufacturer material and data sheets
and pertinent references should also be included in this
manual. As technologists demonstrate competency, it
may also be useful to include a log sheet documenting
the completion of training on each probe set.
One scheme for FISH training is to treat all like-de-
signed probes as a unit, with group 1 including enumer-
ation probes (eg, one color chromosome 8 -satellite
centromere probe, two color X/Y probes); group 2 includ-
ing dual-color, dual-fusion probes (eg, BCR/ABL1, IGH/
BCL2, PML/RARA); group 3 including single-fusion, ex-
tra-signal (ES) probes (eg, ETV6/RUNX1, BCR/ABL1 ES);
and group 4, including break-apart probes (eg, CBFB,
MLL).
Each of the four subgroups has unique features that
should be focused on during training. For enumeration,
the trainee learns to count signals accurately. Particular
emphasis should be placed on distinguishing a “split”
signal (two signals in very close proximity, representing
two chromatids from a single chromosome) from two true
separate signals. For the dual-color, dual-fusion translo-
cation probes, for which the abnormal pattern is typically
represented by the presence of two fusion signals, the
trainee’s goals are to learn the criteria necessary for
labeling two signals as overlapping or fused and to rec-
ognize other clinically significant variant patterns [eg, a
t(9;22;15) that would not yield a typical dual-fusion pat-
tern but would be detected at initial diagnosis by the high
level of single-fusion cells present]. The ES translocation
probes are probe sets for which the abnormal pattern is
represented by a single fusion plus a small extra signal
representing a residual portion of one of the involved loci.
The goals for the trainee are to learn to distinguish two
overlapping signals from technical artifact and to learn to
differentiate a small true residual signal from nonspecific
hybridization or debris. For break-apart probe analyses,
probes for the region 5 of a designated breakpoint,
labeled with one color, and probes for the region 3 of the
breakpoint, labeled in another color, are assessed. For
these probes, an overlapping red/green or fused yellow
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signal represents the normal pattern, and separate red
and green signals indicate the presence of a rearrange-
ment. Here, the emphasis should be on judging the dis-
tance between a red and a green signal that is necessary
to call them “separate,” to meet criteria for designating
the cell abnormal.
The following training scheme is used to illustrate how
to ensure comparability of scoring between different
technologists and to ensure achievement and mainte-
nance of competency in evaluating FISH results for the
BCR/ABL1 dual-color, dual-fusion probe set.
1. The trainee should read through the laboratory FISH
training manual, including probe manufacturer’s material
and data sheet, and review how the signal patterns in the
interphase cell relates to the metaphase cell chromo-
somal aberration under study.
2. Training should begin with assessment of a positive
diagnostic specimen that has been shown to have a
straight-forward dual-fusion positive pattern in the major-
ity of cells, eg, two fusion signals, one separate BCR, and
one separate ABL1 signal. An experienced technologist
should sit with the trainee and describe in detail how the
slides and microscope fields are to be scanned, how to
judge whether the hybridization reaction is adequate,
how to designate an individual cell’s pattern, and how to
tabulate results.
3. The trainee should then score a series of known
positive and negative cases. Previously scored FISH
cases, if stored in the freezer, can be rescored months
after their initial preparation. The positive cases should
include both diagnostic cases (with high percentages of
BCR/ABL1 fusion-positive cells), as well as follow-up
cases (with low percentages of BCR/ABL1 fusion-positive
cells). In addition, cases with variant FISH patterns, such
as those with a three-way translocation [eg, t(9;22;15)],
which would be expected to have a single fusion rather
than a double fusion pattern, could also be included.
4. After the trainer has confidence in the trainee’s
scoring, the trainee should score a series of cases inde-
pendently, and the results should be correlated between
the scorers. There should be complete agreement be-
tween scorers as to the final diagnosis of the case, nor-
mal or abnormal (eg, BCR/ABL1 fusion present or not),
and there should be close agreement between the per-
centages of abnormal cells scored. If, on the series of
positive cases, the trainee consistently gets a lower or
higher rate of abnormal cells than the trainer, side-by-
side scoring should ensue to identify the basis for the
differences, and a new series of abnormal and normal
cases should be evaluated.
Scoring
A routine FISH evaluation should be scored by two tech-
nologists. The technologists should be familiar with any
unique scoring criteria that were established as part of
the test validation process. The technologists must also
have an understanding of general technical problems
that may influence a test result, such as poor slide prep-
aration, chromosomes or interphase nuclei of poor mor-
phology with reduced signal intensity, or over- or
underdenaturation.
Technologists reading FISH must be knowledgeable
about the reason the test is being performed. They
should also be familiar with any previous G-band chro-
mosome findings and any previous FISH study results
that were obtained for that patient. Laboratory personnel
should know manufacturer’s specifications and limita-
tions with respect to the behavior of any probe or probe
set, such as the size of the genomic target, the ex-
pected signal patterns, and the matrix being studied.
For example, paraffin-embedded tissues commonly re-
quire unique evaluation parameters.
Control Probes
CLIA requires the use of standard controls in laboratory
testing, including FISH studies. For metaphase FISH, it is
recommended that clinical FISH tests include control
probes to tag the chromosome(s) of interest. Such
probes afford a limited level of quality control by provid-
ing an internal control of hybridization efficiency. The
target sequence on a normal chromosome serves as the
best control of technical variables. If a probe is used that
does not have an inherent chromosome control signal (ie,
an X or Y chromosome probe analysis in a male with
clonal loss of the Y chromosome), another sample that is
known to have the probe target (a normal 46, XY male for
this example) should be run in parallel with the patient
sample.11
When interphase analysis is performed, a useful con-
trol measure is assessment of several metaphase cells,
when available. Visualizing the probes on metaphase
cells allows for validation that the correct probe was used
for the study and may be used to confirm an abnormal
result. In addition, metaphase assessment may be
needed if an atypical abnormal FISH pattern is observed.
Understandably, some samples, such as hematologic
blood and direct preparations, may not have available
metaphase cells, and use of another internal control (for
another locus on the same chromosome, for example)
may be necessary.
New lots of reagents, including probes, must be tested
before being put into use. Probe lot validation may be
done by comparing the new lot and the old lot of probe
side by side on the same slide preparation and ensuring
that the results are equivalent. To monitor FISH testing
over time to assess adverse technical trends, the labora-
tory should periodically check assay performance (in-




FISH results should be interpreted within the broader
context of probe and analytical validation (ACMG Stan-
dards and Guidelines for Clinical Genetic Laboratories,
Section E: Clinical Cytogenetics), including the laborato-
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ry’s own normative database and confidence interval
established in the ongoing use of any probes. The direc-
tor and/or clinical consultant must have an understanding
of factors intrinsic to cell culture and slide preparation
before FISH evaluation that may influence a result’s inter-
pretation. The interpretation of FISH results should in-
clude consideration of the reason for referral for testing
and, when available, additional laboratory findings in-
cluding conventional cytogenetic analysis, histology, and
immunophenotype.12
Result Reporting
A system for FISH nomenclature, the International System
for Human Cytogenetic Nomenclature (2005), including
both metaphase and interphase analysis, has been de-
veloped.13 Although the system may seem confusing to
those not working directly with chromosomes, correct
nomenclature designations are important to convey the
precise nature of a result. Metaphase FISH International
System for Human Cytogenetic Nomenclature (ISCN) no-
menclature for a male patient with a 9;22 translocation
resulting in fusion of the BCR and ABL1 genes studied
with conventional banding and with a dual-color, single-
fusion BCR/ABL1 probe set would be written as
46,XY,t(9,22)(q34;q11.2).ish (9;22)(ABL1-;BCR,ABL1),
indicating that the probe sequence from the ABL1 locus is
missing from the derivative chromosome 9 and is pre-
sent on the derivative chromosome 22 distal to the BCR
locus.
The same rearrangement expressed in interphase
FISH nomenclature but using a dual-color, dual-fusion
probe set would be written as follows: nuc ish
(ABL1x3),(BCRx3),(ABL1 con BCRx2), indicating that
each of the probes has been split apart and juxtaposed
by the translocation.
The use of such precise ISCN nomenclature is valued
by laboratories in the initial diagnostic workup and con-
tinued monitoring of patients with a specific chromosome
abnormality. However, the report should also contain a
statement as to the normalcy/abnormalcy of a FISH re-
sult. The report should also clearly indicate the percent-
age of abnormal and normal cells and whether FISH
results are from metaphase or interphase cells or from
both. Specific naming of the probes used to obtain re-
sults, including the name of the manufacturer, must also
be included on the written report. The report must indi-
cate any specific limitations of the assay, some of which
may be described in the probe manufacturer’s package
insert.
The report should clearly indicate both the diagnostic
and prognostic significance of the FISH findings, includ-
ing their relevance to the reason for referral for testing,
the patient’s age, and any pertinent clinicopathologic
findings that may become available. Longitudinal studies
of patients should be compared with their previous ge-
netic test findings, and the report should make clear
recommendations concerning future testing of such pa-
tients, eg, metaphase chromosome analysis, interphase
FISH, and molecular reverse transcription-PCR testing.14
Because of the analyte-specific reagent nature of the
majority of FISH probes, the Food and Drug Administra-
tion has mandated that a disclaimer regarding the use of
analyte-specific reagents must also be included on the
report. Sample wording for the disclaimer was suggested
by the ACMG Standards and Guidelines for Clinical Ge-
netic Laboratories, Section E: Clinical Cytogenetics as
follows: “This test was developed and its performance
characteristics determined by (Name) Laboratory as re-
quired by CLIA ’88 regulations. It has not been cleared or
approved for specific uses by the U.S. Food and Drug
Administration.”
Typical and Atypical Results
The high degree of specificity of probes generally makes
their application and interpretation straightforward. How-
ever, it is not uncommon to have an atypical abnormal
interphase FISH result. For example, findings for a dual-
color, dual-fusion probe may show more than the ex-
pected number of fusion signals in a single cell or small
population of cells or an atypical signal pattern indicating
a probable variant of a disease-associated rearrange-
ment. Although interphase FISH analysis provides infor-
mation only on specific probes used and generally does
not substitute for complete karyotype analysis, it may,
under some disease circumstances, be the preferred
means of identifying an abnormal clone, eg, FISH with the
ATM, CEP12, D13S319, and TP53 probe panel in B-cell
chronic lymphocytic leukemia,6 discrimination of the in-
version 16 in AML (M4-Eo),15 or for the diagnostic abnor-
mality in post-therapy patients who have hypocellular
marrows.
Specific Probe Examples
Dual-Color, Dual-Fusion Probes: BCR/ABL1
All patients with CML have an abnormal clone with fusion
of BCR and ABL1 loci; at least 90% of patients have a
t(9;22)(q34;q11.2), and the rest have a complex or cryp-
tic variant of this translocation. A similar BCR/ABL1 fusion
occurs in 6% of children with ALL and 17% of adults with
ALL.16
The goal for treatment of CML is generally to achieve a
complete cytogenetic metaphase and interphase FISH
remission [ie, no metaphase cells with t(9;22) and inter-
phase FISH results within normal limits] and a molecular
PCR remission. The dual-color, dual-fusion BCR(green)/
ABL1(red) probe (D-FISH) set allows for detection of all
forms of the BCR/ABL1 fusion (yellow), ie, t(9;22), variant
translocations, and cryptic translocations or insertions.2
The probe set is highly sensitive and consistent, and its
technical application and interpretation can be mastered
by most laboratories. Initial FISH studies of CML patients
yield 85 to 99% of BCR/ABL1-positive nuclei in bone
marrow before treatment. When treatment is successful,
the post-treatment percentage of neoplastic nuclei pro-
gressively decreases to less than 1%. Studies indicate
that analysis of 500 nuclei with a D-FISH on bone marrow
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or peripheral blood can detect less than 1% neoplastic
cells.2,17
Strict scoring criteria have been developed for D-FISH
to reliably classify individual cells as either normal or
abnormal.2,16,17 With D-FISH, normal cells have two BCR
and two ABL1 signals (Figure 1A). Patients with a con-
ventional t(9;22)(q34;q11.2) have one BCR, one ABL1,
and two fused BCR and ABL1 signals (Figure 1B). Cells
with multiple copies of the derivative chromosome 22 (Ph
chromosome) have three or more BCR/ABL1 fusion sig-
nals (Figure 1C). Some patients with CML on imatinib
mesylate become “drug-resistant” due to amplification of
the BCR/ABL1 fusion gene; this is observed in individual
neoplastic cells as a cluster of BCR/ABL1 fusion signals
(Figure 1D).
Patients with complex translocations have a unique
signal pattern by D-FISH. For example, consider a patient
with a t(5;9;22)(q31;q34;q11.2). In an abnormal meta-
phase from this patient, a BCR/ABL1 fusion signal occurs
on the derivative 22 (Ph chromosome), a small ABL1
signal occurs on the abnormal chromosome 9, and a
small BCR signal occurs on the abnormal chromosome 5
(Figure 1E). The ABL1/BCR fusion that is normally ob-
served on the abnormal chromosome 9 with D-FISH does
not occur in complex translocations.
Unusual BCR/ABL1 signals are also observed among
patients with cryptic rearrangements that originate from
small insertions involving the BCR and ABL1 loci. These
insertions and other chromosomal rearrangements typi-
cally are not visible by conventional metaphase cytoge-
netic studies but are readily detectable by FISH (Figure 1,
F–H). It is important to use a FISH technique to monitor
response to therapy for patients with a cryptic
rearrangement.
Nearly 20% of patients with a t(9;22)(q34;q11.2) have
any one of three different atypical D-FISH patterns16 (Fig-
ure 1, F–H). Among these patients, there is loss of a
portion of BCR or ABL1 or both of these hybridization
sites normally associated with the break and fusion point
on the abnormal chromosome 9. Laboratory personnel
need to be aware of these variant signal patterns to
adjust their scoring criteria and to use different cutoff
values for normal. For example, the normal cutoff may be
1.2 to 1.8% for two of these atypical signal patterns
(Figure 1, F and G) and less than 1% for other atypical
signal patterns (Figure 1H). It is useful to examine a few
metaphase cells to establish the exact BCR/ABL1 signal
pattern for each patient.
Dual-Color, Single-Fusion, Extra Signal Probes:
ETV6/RUNX1
The FISH assay for the cryptic 12;21 translocation (ETV6/
RUNX1 or, historically, TEL/AML1) has many applications
in the diagnosis and monitoring of acute lymphoblastic
leukemia. The 12;21 translocation is associated with a
good prognosis and occurs in approximately 25% of
childhood B-lineage-ALL, with a peak incidence at ages
2 to 5 years.18,19 The translocation is usually not seen in
infants less than 1 year of age, and in adults with ALL the
frequency is estimated between 1 and 3%.20 In addition
to the detection of the 12;21 translocation, the commer-
cially available TEL/AML1 ES probe (Vysis, Downer’s
Grove, IL) can also ascertain numeric and structural ab-
normalities of chromosomes 12 and 21, which are recur-
ring abnormalities in ALL.
The 12;21 translocation cannot be seen on G-banded
metaphases, and FISH and other molecular methods are
needed to detect this rearrangement. Typically with an
extra-signal, dual-color translocation probe set, one of
Figure 1. Representative interphase nuclei showing D-FISH signal patterns
in cells with various Ph chromosomes. A: Nuclei with two red (ABL1) and
two green (BCR) signals are normal. B: Nuclei that have one red, one green,
and two fusion signals have a balanced t(9;22). C Nuclei that have one red,
one green, and three yellow fusion signals have an extra Ph chromosome. D:
Nuclei that have amplification of the yellow BCR/ABL1 fusion signal will
show multiple copies of the BCR/ABL1 fusion signal. E: Nuclei that have two
red, two green, and one yellow fusion signal have a complex Ph chromo-
some. F: Nuclei that have one red, one green, and one fusion signal either
have a masked Ph chromosome or have loss of the ABL1 and BCR hybrid-
ization sites that are normally observed on the abnormal chromosome 9. G:
Nuclei that have two red, one green, and one yellow fusion signal have loss
of the BCR hybridization site that is translocated to the abnormal chromo-
some 9. H: Nuclei that have one red, two green, and one fusion signal have
loss of the ABL1 hybridization site that normally remains on the abnormal
chromosome 9.
140 Wolff et al
JMD April 2007, Vol. 9, No. 2
the probes is quite long (eg, the Vysis RUNX1 probe is
approximately 500 kb and spans the entire RUNX1 locus
on 21q). An abnormal cell with the translocation would
show the ETV6/RUNX1 fusion as yellow (redgreen on
the derivative chromosome 21), one green signal (unin-
volved chromosome 12), one large red signal (uninvolved
chromosome 21), and one small red signal (extra signal
residual on the chromosome 12 involved in the translo-
cation) (Figure 2B). Although the translocation itself is
cryptic, it is often associated with cytogenetically visible
structural and numeric abnormalities of the chromo-
somes. In a collaborative study of 169 children with t(12;
21)-positive ALL, additional structural chromosomal ab-
normalities were reported in 89.7% of the karyotypes
containing the cryptic translocation, and numeric abnor-
malities were seen in 47%.18
FISH is particularly useful for analysis of ALL cases
with cytogenetically normal diagnostic studies. In addi-
tion to finding the expected 12;21 translocation in many
of these patients, other abnormal patterns, with and with-
out the ETV6/RUNX1 fusion, are also observed.20 For
example, extra RUNX1 signals without an ETV6/RUNX1
fusion can be indicative of the presence of an undetected
high hyperdiploid cell line or gene amplification (Figure 2,
E and F). The finding of extra copies of RUNX1 in an
interphase FISH assay requires correlation with meta-
phase FISH or traditional cytogenetic studies for accurate
interpretation (Figure 2F). The presence of five or more
copies of RUNX1 in an interphase nucleus can suggest
gene amplification. Metaphase chromosome studies of
most cases of RUNX1 amplification show a single copy of
the gene on a normal chromosome 21 and the remainder
of the RUNX1 signals clustered on a duplicated 21, a
marker chromosome, or a ring (Figure 2F). The important
distinction between polysomy 21 (often seen in high hy-
perdiploidy with a good prognosis) and RUNX1 amplifi-
cation (often seen in a near diploid or a pseudodiploid
karyotype and associated with a poor prognosis) is that
with RUNX1 amplification multiple signals are clustered
on one or two, often structurally abnormal, chromosomes.
Abnormal signal patterns for the ETV6 probe can indicate
loss of material from the chromosome 12 short arm (de-
letion 12p; Figure 2C) or rearrangement of 12p. Aberra-
tions involving 12p have long been appreciated as a
recurring abnormality in both childhood and adult ALL,
occurring in 4 to 9% of patients.12
Dual-Color, Break-Apart Probe: MLL
Structural rearrangements of the mixed lineage leukemia
(MLL) gene at 11q23 are well-documented recurring ab-
normalities and are observed in de novo and therapy-
related hematologic disorders, including myelodysplastic
syndromes, acute lymphoid, myeloid and biphenotypic
leukemias, as well as secondary AML after treatment with
topoisomerase II inhibitors.21–23 Hematologic malignan-
cies with MLL rearrangement are particularly common in
infants (85% of infantile ALL and 65% of infantile
AML) and can also be observed in children and
adults.24–26
Figure 2. Probe patterns observed at diagnosis in the bone marrow of six patients with childhood B-lineage ALL. In each case, marrow slides were prepared by
standard cytogenetic techniques for chromosome analysis and hybridized with Vysis’ TEL/AML1 ES probe for FISH analysis. Results for A–F (upper left through
lower right), probe pattern first and then interpretation: A: Red, Red, Green, Green; normal, no evidence of abnormality; B: Red, residual Red, Green, Fusion;
typical pattern for t(12;21)(p13;q22); C: Red, residual Red, Fusion; t(12;21) with loss of the TEL (ETV6) locus from the uninvolved 12; D: Red, Red, Green; no
evidence of translocation, loss of one TEL (ETV6) signal consistent with del(12p); E: Red, Red, Red, Red, Red, Green, Green; no translocation, this pattern was
found in a patient with high hyperdiploidy with five copies of chromosome 21; and F: A partial metaphase spread from a patient with no evidence of t(12;21)
but multiple AML1 (RUNX1) signals on a single marker chromosome (AML1 amplification).
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The majority of MLL rearrangements occur as a result
of an established chromosomal translocation involving
11q23; however, cryptic insertions and complex abnor-
malities that can mask its involvement are not uncommon.
Occasionally, MLL is rearranged by partial tandem du-
plication and subsequent self-fusion, often in association
with trisomy 11 or with a normal karyotype. Conventional
cytogenetic analysis identifies the principal 11q23 trans-
locations [eg, t(4;11)(q21;q23)], but it can neither dis-
criminate cryptic MLL translocations from del(11)(q23)
nor confirm the involvement of the MLL gene in cases
with undefined or rare 11q23 translocation partners. The
accurate detection and characterization of MLL rear-
rangements often requires the use of more than one
technique. Conventional cytogenetics and FISH are the
first choice for describing the aberrant chromosomes,
and MLL assessment may be complemented by molec-
ular methods, particularly when cytogenetic results are
discrepant or incomplete.
Given the promiscuity of the MLL gene (it is involved
in 80 different translocations), the most effective and
appropriate FISH probe for detecting the MLL rear-
rangements is a dual-color break-apart probe made of
differentially labeled (red and green) DNA segments
located on either side of the MLL breakpoint cluster
region. The separation of red and green signals indi-
cates MLL break for the 3 and 5 regions of the gene.
In normal cells, the two probes co-localize to produce
two yellow fusion signals, whereas in the presence of a
translocation involving the MLL gene, one of the fusion
signals splits, resulting in a characteristic 1red-1green-
1yellow fusion signal pattern. The advantage of this
kind of FISH assessment is that it can detect all recur-
rent and possibly novel MLL rearrangements in a sin-
gle experiment. For cases with complex MLL rear-
rangements, FISH on metaphase cells often provides
clues to understanding the underlying mechanism and
allows for correct identification of the chromosome
abnormality.
Occasionally, an atypical pattern is observed in
which the 3 telomeric red signal is lost. This 0red-
1green-1fusion pattern has been assumed to indicate
the presence of an MLL rearrangement because the
two signals have separated. The loss of the 3 red
signal (20% of MLL rearrangements) is thought to arise
from a concurrent deletion event, in which the retention
of 5 MLL is consistent with the preservation of the
more important of the two fusion products.27,28 Other
types of variant signal patterns, such as deletion of the
5 MLL region (Figure 3), have also been observed.
However, because of the rarity of such variants, the
clinical significance is not clear.
Conclusions
FISH has now become an invaluable tool in defining
and monitoring acquired chromosome abnormalities
associated with hematologic and other neoplasias. The
implementation of FISH into the routine diagnostic lab-
oratory requires rigorous attention as to when it is
appropriate to apply the technology, a very systematic
approach to the validation of probes and technical
procedures involved in FISH, and the training of indi-
viduals that will perform the testing, and a comprehen-
sive, but understandable, means of reporting out re-
sults. As the number of critical loci involved in
neoplastic chromosome rearrangements or numeric
abnormalities continues to expand, the diversity of
FISH probes and unique probe sets will undoubtedly
improve. FISH has become an important means both
for definition of the initial chromosome changes in a
disease process, as well as a reliable means for the
Figure 3. G-banded metaphase spread [47,XY,11,t(11,21)(q23;q22)] on the right with arrows showing the two normal copies of chromosome 11 and derivative
chromosomes 11 and 21. MLL break-apart probe FISH analysis on the same metaphase cell (left) showing the two normal copies of chromosome 11 (yellow),
the red derivative chromosome 21 [der(21)] signal, and the derivative chromosome 11 (arrow).
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ongoing monitoring of response to therapy and dis-
ease remission.
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